Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.140 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
37 38 Next >
Cassava Sciences Is in a Bleak Midwinter Waiting for Spring and Better Days
SAVA stock is driven by updates on clinical Phase 3 trials and lots of irrationality. Meanwhile, an FDA approval may take quite some time. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Eargo (NASDAQ:EAR) shares rose 10.... 
Via Benzinga
Why Cassava Sciences Is Still a High-Risk Play
As it's not set in stone that Cassava Sciences will be able to bring simulfilam to market, you should approach SAVA stock cautiously. 
Via InvestorPlace
23 Stocks Moving in Wednesday's Pre-Market Session
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) rose 64.9% to $2.54 in pre-market trading after gaining around 5% on Tuesday. Roth Capital recently initiated coverage on the... 
Via Benzinga
Keep an Eye on $60 as a Target Price for Cassava Sciences
As long as you're using a moderate position size, it's fine to hold SAVA stock as it has a tendency to move fast and far from time to time. 
Via InvestorPlace
This Is What Whales Are Betting On Cassava Sciences
Someone with a lot of money to spend has taken a bearish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Check Out What Whales Are Doing With SAVA
Someone with a lot of money to spend has taken a bearish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For Feb. 11, 2022: Cassava Sciences, Cleveland Cliffs, GameStop, and More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago, Would Be Worth This Much
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 53.42% on an annualized basis. 
Via Benzinga
Cassava Sciences Whale Trades Spotted
Someone with a lot of money to spend has taken a bullish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Does Cassava Sciences and Its Alzheimer’s Drug Really Have What It Takes?
Can Cassava Sciences' Simufilam drug really treat Alzheimer's? Who really knows. SAVA stock is pure speculation either way. 
Via InvestorPlace
5 Short Squeeze Candidates To Watch: Vinco Ventures, TSR Inc, Biofrontera And More
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.... 
Via Benzinga
The End Result May Be Worth the Wait With Cassava Sciences Stock
SAVA stock will continue to trade sideways until the moment of truth arrives for its drug candidate Simufilam. 
Via InvestorPlace
Short Squeeze Activity: New Players, Same Game, Different Results
Short squeezes will remain a big story in the financial news media until heavily shorted stocks that have been pushed up by individual investors come crashing back to earth. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Cassava Sciences Is an Exciting Roll-the-Dice Biotech Trade
Take a wild ride -- but keep your position size small, please -- as SAVA stock could return to all-time highs or plummet to new depths soon. 
Via InvestorPlace
Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)
Via AB Newswire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
Via AB Newswire
Topics Bonds Stocks
Cassava Sciences Stock Is Still Risky but Has Plenty of Upside Potential
Among the plethora of high-risk, speculative, clinical-stage biotech plays out there, SAVA stock is one of the better bets out there. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Peering Into Cassava Sciences Inc's Recent Short Interest
Cassava Sciences Inc's (NASDAQ:SAVA) short percent of float has risen 22.31% since last its last report. The company recently reported that it has 10.25 million shares sold short... 
Via Benzinga
Cassava Sciences Stock Is Worth Almost 4x More After Adjusting for Risk
Cassava Sciences stands to gain using probability methods. On a risk-adjusted basis, SAVA stock is worth 3.7 times more, despite its downside. 
Via InvestorPlace
7 High Risk Stocks That Are Worth The Volatile Vibes
These seven high risk stocks made wild moves in 2021, but still have the potential to rocket higher. All are full of both risk and reward. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Global Alzheimer’s Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028
Palm Beach, FL –January 4, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss,... 
Via FinancialNewsMedia
How Are The Shorts Feeling About Cassava Sciences Inc?
Cassava Sciences Inc's (NASDAQ:SAVA) short interest has increased 22% since the last report. The company recently reported that it has 10 million shares sold short, which is... 
Via Benzinga
7 of the Best Meme Stocks for 2022 to Buy Now
Although the meme stocks phenomenon is sagging in popularity, these seven current and/or former Reddit favorites could make another "to the moon" move or two in 2022. 
Via InvestorPlace
Cassava Sciences Whale Trades Spotted
A whale with a lot of money to spend has taken a noticeably bearish stance on Cassava Sciences. Looking at options history for Cassava Sciences (NASDAQ:SAVA) we detected 12... 
Via Benzinga
Investing In This Alzheimer’s Drug Maker Risky But Could Be Quite Rewarding
Coming up with the medicine for Alzheimer's Disease can be really good for a company and although it might seem risky, with great risks come great rewards. 
Via Talk Markets
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.